Opinion and Comment 遺伝子治療の価格設定の特殊な例 2014年9月1日 Nature Biotechnology 32, 9 doi: 10.1038/nbt.3003 Gene therapy companies that pursue high, one-time payments for their products risk a backlash from payors. A better solution may lie in a pay-for-performance model. Full text PDF 目次へ戻る